Moderna said on Tuesday its coronavirus disease 2019 vaccine is proving highly effective in a major trial, a second ray of hope in the global race for a shot to tame a resurgent virus that is now killing more than 8,000 people a day worldwide.
The company said its vaccine appears to be 94.5-percent effective, according to preliminary data from Moderna’s ongoing study. A week ago, competitor Pfizer Inc. announced its own vaccine appeared similarly effective — news that puts both companies on track to seek permission within weeks for emergency use in the United States.
The results are “truly striking,” said Dr. Anthony Fauci, the US government’s top infectious diseases expert. Earlier this year, Fauci said he would be happy with a Covid-19 vaccine that was 60-percent effective.
A vaccine can’t come fast enough, as virus cases topped 11 million in the US over the weekend — 1 million of them recorded in just the past week — and governors and mayors are ratcheting up restrictions ahead of Thanksgiving. The pandemic has killed more than 1.3 million people worldwide, over 245,000 of them in the US.
Stocks rallied on Wall Street and elsewhere around the world on rising hopes that the global economy could start returning to normal in the coming months. Moderna was up 7.5 percent in the morning, while companies that have benefited from the stay-at-home economy were down, including Zoom, Peloton and Netflix.
Dr. Stephen Hoge, Moderna’s president, welcomed the “really important milestone” but said having similar results from two different companies is what’s most reassuring.
“That should give us all hope that actually a vaccine is going to be able to stop this pandemic and hopefully get us back to our lives,” Hoge told The Associated Press. He added: “It won’t be Moderna alone that solves this problem. It’s going to require many vaccines” to meet the global demand.
The National Institutes of Health helped create the vaccine Moderna is manufacturing, and NIH’s director, Dr. Francis Collins, said the exciting news from two companies “gives us a lot of confidence that we’re on the path towards having effective vaccines.”
STILL A DARK TIME AMID COVID
But “we’re also at this really dark time,” he warned, saying people can’t let down their guard during the months it will take for doses of any vaccines cleared by the Food and Drug Administration (FDA) to start reaching a large share of the population.
Scientists not involved with the testing were encouraged by the early findings but cautioned that the FDA still must scrutinize the safety data and decide whether to allow vaccinations outside of a research study.
“We’re not to the finish line yet,” said Dr. James Cutrell, an infectious disease expert at UT Southwestern Medical Center in Dallas. “If there’s an impression or perception that there’s just a rubber stamp, or due diligence wasn’t done to look at the data, that could weaken public confidence.”
If the FDA allows emergency use of Moderna’s or Pfizer’s candidate, there will be limited, rationed supplies before the end of the year.
Both vaccines require people to get two shots, several weeks apart. US officials said they hope to have about 20 million Moderna doses and another 20 million doses of the vaccine made by Pfizer and its German partner BioNTech to use in late December. SOVEREIGNPH WITH AP